平方毫米
泛素连接酶
泛素
基因敲除
体内
癌症研究
蛋白酶体
蛋白质降解
A549电池
化学
癌变
癌症
药理学
细胞培养
细胞生物学
细胞
医学
生物
生物化学
内科学
生物技术
遗传学
基因
作者
Shipeng He,Junhui Ma,Yuxin Fang,Ying Liu,Shanchao Wu,Guoqiang Dong,Wei Wang,Chunquan Sheng
标识
DOI:10.1016/j.apsb.2020.11.022
摘要
The dose-related adverse effects of MDM2‒P53 inhibitors have caused significant concern in the development of clinical safe anticancer agents. Herein we report an unprecedented homo-PROTAC strategy for more effective disruption of MDM2‒P53 interaction. The design concept is inspired by the capacity of sub-stoichiometric catalytic PROTACs enabling to degrade an unwanted protein and the dual functions of MDM2 as an E3 ubiquitin ligase and a binding protein with tumor suppressor P53. The new homo-PROTACs are designed to induce self-degradation of MDM2. The results of the investigation have shown that PROTAC 11a efficiently dimerizes MDM2 with highly competitive binding activity and induces proteasome-dependent self-degradation of MDM2 in A549 non-small cell lung cancer cells. Furthermore, markedly, enantiomer 11a-1 exhibits potent in vivo antitumor activity in A549 xenograft nude mouse model, which is the first example of homo-PROTAC with in vivo therapeutic potency. This study demonstrates the potential of the homo-PROTAC as an alternative chemical tool for tumorigenic MDM2 knockdown, which could be developed into a safe therapy for cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI